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1. Introduction
C h ro n ic  obstructive  pu lm onary  disease 
(COPD) is characterised by progressive loss of 
lung function and oxygen uptake capacity. As a 
consequence, extensive morbidity and mortality 
do occur in these patients due to complications of 
hypoxaemia such as polycythaemia, pulmonary 
hypertension, cor pulmonale and cardiac arrhyth­
mias. In the course of the disease, periods with 
arterial oxygen desaturations may first occur dur­
ing R EM  sleep [1], due to hypoventilation [2]. 
Prospective studies estimate that this occurs in 
25-100%  of the patients with COPD who are 
normoxaemic during the day, depending on the 
definition of desaturation and the severity of the 
disease [1,3,4].
T reatm ent modalities to improve nocturnal 
saturation in these patients include supplemental 
oxygen, respiration-stimulating agents, assisted 
ventilation and training of the respiratory mus­
cles. In this article we will discuss some aspects of
* Tel.: (31-8895) 59911; fax: ( +  31-8895) 59290.
the breathing disorders during sleep that may 
occur in patients with COPD and the different 
treatment modalities.
2. Diagnosis
2.1. Polysomnography
Nocturnal breathing disorders and their under­
lying mechanisms can be assessed by polysomnog­
raphy. During the night arterial oxygen satura­
tion, carbon dioxide tension measured in respira­
tory air, arterially or transcutaneously, thoraco­
abdominal movements, oscillation in oesophageal 
pressure and sleep stages are recorded. Sleep 
stages are recorded to define the adequancy of 
sleep, i.e. is there enough sleep to be representa­
tive, and conformation of REM sleep to catch the 
presence of REM sleep-related phenomena [5]. 
When analysing polysomnography records, sev­
eral irregular breathing patterns can be distin­
guished. Central apnoea is defined as the absence 
of P C 0 2 oscillations or oro-nasal airflow for at 
least 10 s, in combination with absent chest wall
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movements or oesophageal pressure swings. Ob­
structive apnoea is defined as the absence of 
P C 0 2 oscillations or oro-nasal airflow for at least 
10 s, in combination with a normal or decreased 
chest wall movement. Hypopnoea is defined as an 
episode of alveolar hypoventilation of at least 10 
s detected by an increase in P C 0 2. Central hypop­
noea is caused by a decrease in central ventilatory 
drive, and ideally it should be deduced from a 
param eter that measures ventilatory drive more 
or less directly. Integrated respiratory muscle 
EM G or oesophageal pressure oscillations are 
such parameters. Indirect parameters of a de­
crease in ventilatory drive, such as movements of 
the thoracic wall, should be interpreted with ex­
treme caution. The term central hypoventilation is 
often used to indicate hypoventilation of a non­
obstructive origin, such as respiratory muscle fail­
ure, although the latter is no central problem in 
the strict sense. Obstructive hypopnoea is associ­
ated with a normal or even increased central 
ventilatory drive and decreased ventilation. A 
combination of central and obstructive breathing 
disorders may also be present. These irregular 
breathing patterns occur most frequently during 
REM  sleep.
Several studies have tried to find daytime pa­
rameters to predict nocturnal saturation in pa­
tients with COPD, because nocturnal hypoxaemia 
caused by central hypopnoea is often symptom- 
less. Although, polycythaemia, pulmonary hyper­
tension, cor pulmonale, morning headache or 
generalised fatigue indicate the presence of se­
vere disturbances. Daytime S a 0 2 (r = 0.87), 
P a C 0 2 ( r =  -0 .73), F E ^  (r = 0.61), the hyper­
capnie ventilatory response (HCVR) (r =  0.41) 
and maximal inspiratory mouth and transdi- 
aphragmatic pressures (r = 0.65 and 0.53, respec­
tively) are related to nocturnal saturation in 
groups of patients [4,6,7]. However, none of these 
variables is able to predict nocturnal saturation in 
the individual patient, precisely enough to re­
place polysomnography. Therefore, polysomnog­
raphy or a screening oximetry is advised in pa­
tients with a daytime P a 0 2 between 7.3-11.0 kPa 
combined with one of the following disorders: 
polycythaemia, pulmonary hypertension, cor pul­
monale, PaCOa > 45 mmHg, morning headache
or generalised fatigue [8], an H CV R below 3.5 
1 • m in" 1 • kPa~* [4] or low maximal inspiratory 
pressures (females <  5.0 kPa, males < 7.5 kPa)
[9].
3. Mechanisms involved in the occurrence of noc­
turnal desaturations
In many patients with COPD, transient de­
creases in nocturnal arterial oxygen saturation 
occur. This may be caused by a variety of factors. 
The importance of these factors will be outlined 
below.
Hypoventilation (“central hypopnoea”); During 
sleep, ventilation is reduced in normal subjects 
and in patients with COPD [3]. This hypoventila­
tion is most severe during R E M  sleep. The cause 
of this phenomenon is not fully understood but 
may be related to a decrease in brainstem respi­
ratory activity, diminished respiratory responses 
to hypoxia and hypercapnia during R EM  sleep, 
and a loss of inspiratory activity of intercostal 
muscles and accessory respiratory muscles. The 
latter is due to the REM -sleep-related supraspinal 
inhibition of the gamma motor neuron drive.
«
Since the gamma m otoneuron innervation of the 
diaphragm is sparse, this muscle is relatively 
spared. These changes occur in patients with 
COPD as well as in healthy subjects, but the 
consequences are worse in the first group. Firstly, 
patients with COPD often have somewhat low­
ered arterial oxygen tensions awake. The starting 
position on the oxygen saturation curve is closer 
to the steep part, so a small drop in P a 0 2 during 
the night causes a large fall in S a 0 2. Secondly, 
the flattened diaphragm cannot compensate for 
the decreased activity of intercostal and accessory 
muscles during R EM  sleep. Thirdly, desaturating 
patients have a larger decrease in functional 
residual capacity during hypopnoea [2]. Finally, 
the ventilatory responses in some patients with 
COPD during wakefulness are already lowered, 
thus further contributing to the degree of noctur­
nal desaturations [4].
Ventilation /  perfusion inequality: Previously, 
this was considered as the major cause of REM- 
sleep-related hypoxaemia in patients with COPD
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[3]. However, these studies were based on the 
assumption that there is a steady state of gas 
transfer, which does not exist during REM  sleep
[10]. It is inevitable, though, that hypoventiiation 
during R E M  sleep is accompanied by some alter­
ation in ventila tion/perfusion matching.
Abnormal hypercapnic and hypoxic responses: 
Ventilatory responses during wakefulness to hy- 
percapnia and hypoxia seem to be lower in hy­
poxic patients [3],
Obstructive sleep apnoea /  hypopnoea syndrome
(OSAHS): OSAHS, defined as a sleeping disor­
der in which obstructive apnoea/hypopnoea 
events occur more than 10 times per sleeping 
hour, may affect 1 -4%  of the general population 
[3]. Thus, a similar percentage of patients with 
COPD may also suffer from OSAHS, but the 
prevalence is most probably not higher than in 
the general population.
4. Consequences of nocturnal hypoxaemia
W hen desaturations are severe and result in 
nocturnal hypoxaemia, side-effects may occur. 
Nocturnal hypoxaemia is associated with pul­
monary hypertension [11-14], which causes cor 
pulmonale [15,16], Furthermore, polycythaemia 
may exist [17]. Cardiac arrhythmia is an uncom­
mon complication, but premature ventricular 
complexes, bradycardia and tachycardia have 
been described [18]. In  the study of Levi-Valensi 
and colleagues [11] a correlation (r  =  0.33) was 
found betw een the total duration of saturation 
dips and pulmonary hypertension in 40 patients 
with COPD and a daytime P a 0 2 between 8.0-9.3 
kPa (60-70 mmHg). Pulmonary hypertension was 
only present in 6 out of 18 patients who desatu­
rated. These findings are in line with the data 
published by Fletcher and co-workers [12]. These 
authors found that the systolic pulmonary arterial 
pressure was significantly higher in desaturating 
(n =  36) than  in non-desaturating (n = 13) pa­
tients with COPD and with a daytime P a 0 2 > 8 
kPa (60 mmHg) (33 versus 26 mmHg, p  < 0.01). 
In the study of Boysen and colleaques [13] the 
effects of hypoxaemic episodes on the pulmonary 
artery pressure (Pap) during the night were stud­
ied in 4 patients with COPD. All nocturnal
episodes of desaturations were accompanied by 
elevations in the Pap. Low flow oxygen abolished 
the drops in arterial oxygen saturation and no 
elevations in the Pap were observed. Weitzen- 
blum and co-workers [14] investigated prospec- 
tively the changes in P a 0 2 and Pap in 93 hypox­
aemic patients with severe COPD for at least 5 
years. In 27 patients an increase > 5 mmHg in 
the Pap was observed. Only in this patient group 
was a marked worsening of the P a 0 2 seen, which 
was not observed in the remaining 66 patients. 
There was a significant correlation between the 
change in Pap and P a 0 2 ( r =  —0.50, p  <0.001). 
All these studies suggest that nocturnal hypox­
aemia is associated with the development and 
progression of pulmonary hypertension.
The relationship between daytime or nocturnal 
hypoxaemia and cor pulmonale was studied by 
Midgren and colleagues [16]. Seven of the 21 
included patients with COPD had suffered from 
right ventricular failure at least once. They had 
lower P a 0 2 and higher P a C 0 2 levels than the 
patients without a history of right heart failure. 
They were more hypoxaemic during the night. In 
the group as a whole no correlations were found 
between daytime oxygenation and right ventricu­
lar hypertrophy. However, oxygen saturation dur­
ing the night and right ventricular hypertrophy 
were inversely related (r = -  0.56, p  < 0.01). 
Therefore, in normoxic patients during the day 
but with signs of right heart failure a polysomnog­
raphy is advised.
The effects of nocturnal hypoxaemia on sur­
vival are not clear yet. One study is available in 
which survival in desaturating and non-desaturat- 
ing patients is compared [1]. One hundred and 
sixty-nine patients with COPD and a FEV t of 
35% predicted, who were all normoxaemic 
(daytime PaO 2 > 8.0 kPa [60 mmHg]), were inves­
tigated. Desaturating patients had a worse sur­
vival than non-desaturating patients (mean sur­
vival 2.9 [1.7] and 3.7 [1.7]) years, respectively). 
Also, 5-year survival was significantly better in 
the non-desaturating group (after stratification 
for oxygen suppletion). However, this was a retro­
spective multicentre study in which patients were 
included who were already being treated with 
oxygen.
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5. Treatment of nocturnal hypoxaemia
5.1, Supplemental oxygen
Studies on the effects of oxygen have only 
been performed in patients who were also hypox- 
aemic during the day. In these studies an im­
provement of the quality of life [19], some rever­
sal of ECG changes (less right axis deviation or 
the loss of the finding of “ p-pulmonale” [19]) and 
a decrease in the pulmonary artery pressure com­
bined with an increase in cardiac output [20] were 
observed. Supplemental oxygen during the night 
can be given safely because it improves nocturnal 
oxygenation with only a small rise in P a C 0 2 [21]. 
Nocturnal oxygen supply should be titrated indi­
vidually during a full night and should be con­
trolled by oximetry. The mean nocturnal arterial 
oxygen saturation should be more than 90% [22].
5.2. Ventilatory stimulants
Stimulating agents may be considered if any 
reserve-capacity of the ventilatory pump is pre­
sent. The progestogens medroxyprogesterone ac­
etate and chlormadione acetate increased day­
time P a 0 2 and decreased PaC0 2, but the effects 
on nocturnal saturation were marginal or absent 
in the whole group of patients. Nevertheless, for 
the individual patient, chlormadione acetate may 
have a substantially positive effect on day- and 
nighttime blood gas values [23,24]. Acetazo- 
lamide, a carbonic anhydrase inhibitor, stimulates 
ventilation presumably by inducing metabolic aci­
dosis. In a 1-week double-blind, placebo-con­
trolled study it caused an improvement in the
mean daytime P a 0 2 of 1.9 kPa (14 mmHg) and in 
the mean nocturnal saturation of 4% [24]. How­
ever, acetazolamide may be ineffective in some 
patients. Daytime parameters, however, failed to 
select the non-responders. Recently, Mulloy et al. 
[25] showed in a 3-week double-blind, placebo- 
controlled study that theophylline improved gas 
exchange during sleep in 10 patients with severe 
COPD. The mean S a 0 2 asleep improved by 2% 
while the mean transcutaneously measured P C 0 2 
asleep decreased by 0.5 kPa (4 mmHg). Loop 
diuretics have an adverse effect on nocturnal 
saturation since they can result in a metabolic 
alkalosis and blunt the respiratory drive [15].
5.3. Assisted ventilation
Continuous positive pressure ventilation dur­
ing the night, administered through a nasal mask, 
can effectively reduce inspiratory muscle effort 
during sleep, but S a 0 2 and transcutaneously 
measured P C 0 2 were unaffected [26]. The effects 
of nasal intermittent positive pressure ventilation 
were described in an uncontrolled study by Car­
roll and co-workers [27]. They showed in 4 hypox- 
aemic patients with COPD and with a mean 
FEVj of 19% of the predicted value that daytime 
P a 0 2 did not change significantly while daytime 
P a C 0 2 decreased by 1.1 kPa (14.3 mmHg). Oxy­
genation during the night improved. This was 
shown by a decrease in the time spent below 90% 
S a 0 2 from 100 to 40% of the total monitoring 
time. However, the patients slept less well, as 
shown by a decrease in R EM  sleep from 12 to 
5% of the monitoring time.
5.4. Training o f  the respiratory muscles
Target-flow inspiratory muscle training (TF- 
IMT) is the most recently described form of ther­
apy [28]. During 10 weeks, 10 patients with COPD 
underwent TF-IM T at 60% of their maximal in­
spiratory mouth pressure (P Imax) and 10 control 
patients with COPD received sham TF-IM T at 
10% of PI miUi • Two times a day patients trained 
on an incentive flow m eter with an added resis­
tance for 15 min. P I max, maximal inspiratory 
transdiaphragmatic pressure (Pdi), and respira­
tory muscle endurance improved significantly in 
the 60% training group. No changes were found 
in the sham training group. The improved respi­
ratory muscle function resulted in a mean in­
crease in mean nocturnal saturation by 2% (p  =
0 .01); the most pronounced improvements (up to 
7%) were found in patients with the lowest noc­
turnal saturations.
6. Clinical consequences and recommendations
Although positive effects of the different forms 
of therapy on nocturnal saturation have been 
described, no placebo-controlled studies have
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Table 1
Treatm ent of nocturnal hypoxaemia
Daytime Nocturnal Treatment
oxygenation oxygenation modality
P a 0 2 7 .3-8.0 kPa S a 0 2 < 90% Continuous
(55-60 mmHg) oxygen
combined with
Ht >  55%  or pulmonary
artery pressure > 3 kPa
or cor pulmonale
P a 0 2 > 7.3 kPa S a 0 2 <85% Oxygen during
(55 mmHg) ( > 2 h) the night
P a 0 2 > 7.3 kPa S a 0 2 85-90% Acetazolamide»
(55 mmHg) theophyllines, 
progestogens, IMT
P a 0 2 — partial arterial oxygen tension; S a 0 2 ~  arterial 
oxygen saturation; H t =  haematocrit; IM T — inspiratory 
muscle training.
been published on the effects on pulmonary artery 
pressure, cor pulmonale and survival. So far it 
has not been recommended, therefore, to pre­
scribe oxygen to patients with mild nocturnal 
hypoxaemia only, since it is an expensive form of 
therapy. An exception is made for patients with 
severe hypoxaemia (S a 0 2 < 85%) for more than 2 
hours while sleeping, because it is unlikely that 
such episodes are harmless [22]. Acetazolamide, 
progestogens, theophyllines and inspiratory mus­
cle training are modalities that can be used to 
trea t nocturnal hypoxaemia, but their effects on 
the occurrence of complications in the long term 
are not known.
Based upon the above-mentioned considera­
tions, nocturnal hypoxaemia (S a 0 2 < 90%) in 
patients with COPD should be treated in the 
following way (Table 1). Supplemental oxygen for 
as close to 24 h /d a y  as is possible [29] should be 
administered if nocturnal hypoxaemia is present 
in combination with a daytime P a 0 2 between 
7.4-8.0 kPa (55-60 mmHg) with evidence of poly- 
cythaemia (Ht >  55%) or pulmonary hyperten­
sion (mean pulmonary artery pressure >  3 kPa 
[20 mmHg]) or clinical signs of cor pulmonale 
[22,30]. Nocturnal oxygen therapy may be consid­
ered in patients with severe episodes of hypox­
aemia (S a 0 2 <  85%) for more than 2 hours dur­
ing the night [22]. The oxygen dose should be 
sufficient to raise the saturation above 90% [22].
Acetazolamide, progestogens, theophylline and 
respiratory muscle training may be considered to 
treat patients with mild hypoxaemia only during 
the night. Polysomnography should be used for 
diagnosing nocturnal hypoxaemia, its underlying 
mechanisms, and for establishing the presence of 
REM sleep in the diagnostic night. Oximetry can 
be used for screening purposes, and for titrating 
the required amount of supplemental nocturnal 
oxygen.
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